Latest Anaplastic lymphoma kinase Stories
- In Phase II studies, Zykadia (ceritinib) shrank tumors in patients with ALK+ NSCLC; comparable overall response in those with or without brain metastases1,2 EAST HANOVER, N.J., June 1, 2015
- Marks first commercial oncology milestone for EMD Serono through the global strategic alliance between Merck KGaA, Darmstadt, Germany and Pfizer ROCKLAND, Mass., May 6, 2015 /PRNewswire/
A study published in The Oncologist on February 26, 2015, challenges the role of fluorescence in situ hybridization (FISH) testing as the current gold standard for detecting EML4-ALK rearrangements
TUCSON, Ariz., Jan. 21, 2015 /PRNewswire/ -- Ventana Medical Systems, Inc.
The Oncology Institute of Hope and Innovation announces first clinical trial of the year. Downey, CA (PRWEB) January 10, 2015 The Oncology Institute
-- CHOP and Penn Medicine Experts Define Riskier Mutations in Neuroblastoma, Setting Stage for Clinical Trial-- PHILADELPHIA, Nov.
The anti-cancer drug Xalkori® is being investigated by the ECOG-ACRIN Cancer Research Group in E4512, a phase III trial. Philadelphia, PA (PRWEB) August
A study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 reports the results of a first-in-human, phase 1 dose escalation trial of crizotinib (XALKORI) in 14 patients with advanced, MET-amplified non-small cell lung cancer (NCT00585195).
- A mania for the use of printing-types; a strong propensity to write for publication.